Organization (Industry)
TELIX PHARMACEUTICALS LIMITED
ClinicalTrials.gov lists TELIX PHARMACEUTICALS LIMITED as lead sponsor of 24 trials, counting the companies grouped under it. TELIX PHARMACEUTICALS LIMITED itself has 17 active development programs and 4 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. Companies grouped under this one are not included. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 3 registered with a 2026 start date. The dashed outline is the pace from the 2 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 4.4 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers TELIX PHARMACEUTICALS LIMITED and 2 companies grouped under it: 24 lead-sponsored trials (23 its own, 1 in the grouped companies) and 4 legal-entity registrations (4 its own, 0 in the grouped companies).
Companies grouped under this page (2)
Shown in this order: most lead trials first.
| Company | Lead trials | Legal entities |
|---|---|---|
| QSAM Therapeutics, Inc. | 1 | 0 |
| Telix Innovations S.A. | 0 | 0 |
Disease areas (32)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Prostatic Neoplasms | 11 |
| Carcinoma, Renal Cell | 10 |
| Kidney Neoplasms | 10 |
| Glioma | 6 |
| Glioblastoma | 4 |
Showing 5 of 32 disease areas.
Trials by start year as sponsor or collaborator (9)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 3 |
| 2025 | 5 |
| 2024 | 5 |
| 2023 | 7 |
| 2022 | 3 |
| 2021 | 3 |
| 2020 | 2 |
| 2019 | 3 |
| 2018 | 1 |
Prediction, not a registry value: median of 35 months from start to primary completion across 8 trials still running at the 2026-10-09 snapshot; 4 of 8 predicted trials reach the 36-month horizon; registered median of 20 months across 11 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (17)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| 68Ga-PSMA-11 | Prostatic Neoplasms | Phase 3 | 2 |
| DOCETAXEL | Prostatic Neoplasms | Phase 3 | 1 |
| 89Zr-TLX250 PET/CT | Carcinoma, Renal Cell | Phase 3 | 1 |
| 89Zr-TLX250 PET/CT | Kidney Neoplasms | Phase 3 | 1 |
| 177Lu-TLX591 | Prostatic Neoplasms | Phase 3 | 1 |
Showing 5 of 17 active programs.
Approved assets (4)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| 68Ga-PSMA-11 | 2 |
| DOCETAXEL | 1 |
| Enzalutamide | 1 |
| Abiraterone | 1 |
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 18% hit target (n=11) | 36% on time (n=11) |
Journals published in (21)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Journal of nuclear medicine : official publication, Society of Nuclear Medicine | 10 |
| Clinical cancer research : an official journal of the American Association for Cancer Research | 4 |
| European urology | 4 |
| EJNMMI research | 3 |
| European journal of nuclear medicine and molecular imaging | 3 |
Showing 5 of 21 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 1 | 1 | 2025-08-12 |
SEC-reported annual financials (4)
Shown in this order: newest fiscal year first; SEC EDGAR XBRL companyfacts, USD as reported.
| Fiscal year | Revenue (USD) | Net income (USD) | R&D (USD) |
|---|---|---|---|
| 2025 | 803,794,000 | -7,125,000 | 171,249,000 |
| 2024 | 516,551,000 | 33,685,000 | 127,930,000 |
| 2023 | 332,978,000 | 4,208,000 | 85,315,000 |
| 2022 | not reported | not reported | not reported |
Financing and grant events (10)
Shown in this order: most recent first.
| Date | Round type | Amount (USD) | Source |
|---|---|---|---|
| 2026-04-23 | Debt financing | 600,000,000 | Sec extracted |
| 2026-04-20 | Other financing | not disclosed | Sec extracted |
| 2026-04-14 | Debt financing | not disclosed | Sec extracted |
| 2026-04-14 | Debt financing | not disclosed | Sec extracted |
| 2026-04-13 | Royalty / licensing | not disclosed | Sec extracted |
Showing 5 of 10 events.
Manufacturing and distribution sites (2)
Shown in this order: severity rank then name.
| Facility | Location | Regulators | Member organization |
|---|---|---|---|
| Telix Innovations | Herstal, BE | EMA, FDA | Telix Innovations |
| Telix Innovations | Liege, BE | EMA, Health Canada | Telix Innovations |
Climate targets, as filed (1)
| Reporting year | Net-zero target |
|---|---|
| 2025 | not disclosed |
Workforce and board diversity, as filed (1)
| Reporting year | Workforce % women | Board % women |
|---|---|---|
| 2025 | not disclosed | not disclosed |
Organization relationships (8)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Medpace Holdings, Inc. | Uses vendor | 1 |
| UCLA Health | Co sponsors trial with | 1 |
| Government of the United States of America | Co sponsors trial with | 1 |
| Mass General Brigham | Co sponsors trial with | 1 |
| Radboud University Medical Center | Co sponsors trial with | 1 |
Showing 5 of 8 relationships.
Latest dated events (44)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-10 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-09-16 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-09-11 | PDUFA decision date | Regulatory decision dates extracted from SEC filings |
| 2026-04-23 | Debt facility | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2026-04-20 | Financing | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
Showing 5 of 44 events.
Biomarker capability evidence (95)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| ALB | Trial sponsor | Named in trial inclusion criteria |
| CSF2 | Trial sponsor | Named in trial inclusion criteria |
| CSF3 | Trial sponsor | Named in trial inclusion criteria |
| DPEP1 | Trial collaborator | Named in trial inclusion criteria |
| FOLH1 | Trial sponsor | Named in trial inclusion criteria |
Showing 5 of 95 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: related companies not grouped here, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, clia clinical laboratory certificates, and biomarkers this organization publishes on.